Hepatitis cirrhosis and

O Prevention and treatment of viral hepatitis may prevent progression to chronic hepatitis, cirrhosis, and end-stage liver disease. 

Hypotonic hyponatremia with an increase in ECF is also known as dilutional hyponatremia. In this scenario, patients have an excess of total body sodium and TBW however, the excess in TBW is greater than the excess in total body sodium. Common causes include CHF, hepatic cirrhosis, and nephrotic syndrome. Treatment includes sodium and fluid restriction in conjunction with treatment of the underlying disorder—for example, salt and water restrictions are used in the setting of CHF along with loop diuretics, angiotensin-converting enzyme inhibitors, and spironolactone.15... 

Generally, a CA 15-3 cutoff of 25 U/ml is used to detect stage I breast cancer. In higher stages, the sensitivity is reported to be much better, which makes it a good test of tumor burden. CA 15-3 is reported to be elevated in other disease conditions such as liver disease (particularly chronic hepatitis, cirrhosis, and carcinoma), some inflammatory conditions (sarcoidosis, tuberculosis, systemic erythematosus), and other carcinoma (lung and ovary). For this reason, positive CA 15-3 results should be interpreted with caution (20,21). 

Edema Adjunctive therapy in edema associated with congestive heart failure (CHF), hepatic cirrhosis, and corticosteroid and estrogen therapy. Useful in edema due to renal dysfunction (eg, nephrotic syndrome, acute glomerulonephritis, chronic renal failure). 

Edema Edema associated with CHF, hepatic cirrhosis, and renal disease, including the nephrotic syndrome. Particularly useful when greater diuretic potential is desired. Parenteral administration is indicated when a rapid onset of diuresis is desired (eg, acute pulmonary edema), when Gl absorption is impaired or when oral use is not practical for any reason. As soon as it is practical, replace with oral therapy. Hypertension (furosemide, oral torsemide, oral) A one or in combination with other antihypertensive drugs. 

Hepatic cirrhosis and ascites In these patients, sudden alterations of electrolyte balance may precipitate hepatic encephalopathy and coma. Do not institute therapy until the basic condition is improved. 

Hypokalemia Hypokalemia prevention requires particular attention to the following Patients receiving digitalis and diuretics for CHF, hepatic cirrhosis, and ascites in aldosterone excess with normal renal function potassium-losing nephropathy certain diarrheal states or where hypokalemia is an added risk to the patient (eg, history of ventricular arrhythmias). 

Edema Edema associated with CHF, hepatic cirrhosis, and the nephrotic syndrome steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism. 

Use bupropion with caution in patients with hepatic impairment (including mild to moderate hepatic cirrhosis) and consider a reduced frequency of dosing in patients with mild to moderate hepatic cirrhosis (see Warnings). 

Methotrexate is approved for use in severe disabling psoriasis recalcitrant to other less toxic treatments. The standard regimen is similar to low-dose therapy used for the treatment of rheumatoid arthritis (see Chapter 36). Although toxicities are similar to those described in the treatment of other diseases, hepatic cirrhosis and unexpected pancytopenia are of special concern given the chronicity of treatment. 

Pharmacokinetics Protein binding 16%-30%. Widely distributed. Primarily excreted unchanged in urine. Removed by hemodialysis. Half-life 0.7-1.2 hr (increased in hepatic cirrhosis and impaired renal function). 

Metabolism and clearance of buspirone is decreased with hepatic cirrhosis and renal disease (Gammans et ah, 1986). 

Kava Piper methysticum) 03/26/2002 Kava is associated with liver-related injury including hepatitis, cirrhosis, and liver failure... 

Recent reports from European health authorities have linked kava to at least 25 cases of liver toxicity, including hepatitis, cirrhosis, and liver failure. The FDA is currently (2002) investigating the health risks of the herbal supplement. Under review are 38 Americans, including a liver transplant recipient, with medical problems associated with kava use. As of February 2002, sales have been halted in Switzerland and are suspended in Britain, Germany is acting to make kava a prescription product and the FDA recommends avoiding kava until safety questions are answered. 

The ammonia tolerance test (C. van Caulaert et al., 1932 E. Kirk, 1936) is carried out with the oral administration of 4—5 g ammonium acetate or 3 g ammonium chloride. Normally, there is no significant elevation of ammonia levels after 30, 60 and 120 minutes. In hepatic cirrhosis and in portacaval anastomosis, there is a clear elevation with delayed normalization. (49)... 

Keohane, RR, Attrill, H., Grimble, G., Spiller, R., Frost, R, Silk, D.B.A. Enteral nutrition in malnourished patients with hepatic cirrhosis and acute encephalopathy. X Parent. Ent. Nutr. 1983 7 346-349... 

Variation in plasma protein concentrations can occur secondary to decreased albumin concentrations associated with hepatic cirrhosis, and nephrotic syndrome (Table 2). Increased (apadd glycoprotein concentrations are associated with the stress response to disease states such as myocardial infarction, inflammatory disease, and postsurgically. " A more relevant problem... 

Furosemide is a widely used loop diuretic indicated for the treatment of different pathological conditions such as congestive heart failure, hepatic cirrhosis, and chronic renal failure. It has a narrow absorption window and mainly absorbed from the stomach and the upper part of the small intestine. Following administration of furosemide, the natriuretic effect rapidly disperses and is concealed before the next administration. This problematic aspect in furosemide therapy is mostly attributed to the natural homeostatic compensatory mechanisms. Lately, it has been demonstrated that the diuretic and natriuretic effects of furosemide can be significantly improved, following a continuous input (intravenous infusion) compared to immediate release DFs. Beside the narrow absorption window, this pharmacodynamic feature of the drug provides another rationale for the development of a GRDF for furosemide. 

In patients who are susceptible to cardiac dysrhythmias, restriction of caffeine may be indicated. Caffeine can also add to the rise in renin and noradrenaline that occur in hepatic cirrhosis and can also considerably aggravate diarrhea in patients with irritable bowel syndrome (SEDA-15,1). 

Hepatic cirrhosis is not a susceptibihty factor, according to the results of a study in 72 patients with hepatic cirrhosis and 72 controls, who received 100-150 ml of low-osmolar contrast media intravenously for abdominal or chest CT scans (174). Serum creatinine was measured before and 48-72 hours after the administration of the contrast agent. The incidence of contrast nephrotoxicity was comparable in the two groups (two patients in the cirrhosis group and one control). 

The ability of sulindac to inhibit prostaglandin synthesis and impair renal function has been confirmed in a different high-risk group, namely patients with hepatic cirrhosis and ascites [82]. We have also identified the development of profound acute kidney injury in risk prone patients who received sulindac for several days to weeks. Collectively, these studies suggest caution in accepting any NSAID as being "renal sparing". 

Other reported dangers are the kava-containing supplements. Supplements containing the herbal ingredient kava are promoted for relaxation. For instance, kava is known to relieve stress, anxiety, and tension for sleeplessness, and menopausal symptoms. There has not yet been a determination from FDA that kava-containing products have the ability to perform such benefits. Kava-containing products have been associated with liver-related injuries, including hepatitis, cirrhosis, and liver failure. 

Liver disease is the most important cause of increased transaminase activity in serum. In most types of liver disease, ALT activity is higher than that of AST exceptions may be seen in alcoholic hepatitis, hepatic cirrhosis, and liver neoplasia. In viral hepatitis and other forms of liver disease associated with acute hepatic necrosis, serum AST and ALT... 

There is epidemiologic evidence to suggest an increased prevalence of duodenal ulcers in patients with certain chronic diseases, but the pathophysiologic mechanisms of these associations are uncertain. A strong association exists in patients with systemic mastocytosis, multiple endocrine neoplasia type 1, chronic pulmonary diseases, chronic renal failure, kidney stones, hepatic cirrhosis, and ai-antitrypsin deficiency. An association may exist in patients with cystic fibrosis, chronic pancreatitis, Crohn s disease, coronary artery disease, polycythemia vera, and hyperparathyroidism. 

HAV is primarily responsible for acute hepatitis. It is most often linked to sporadic events of contaminated food in the United States and to international travel, and is usually a self-limited disease. HBV and HCV are primarily responsible for the development of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Immunomodulatory therapy and direct antiviral agents have been developed for both HBV and HCV. These therapeutic modalities require long courses of therapy and are associated with limited success. This chapter will focus on the pathophysiology, clinical course, and management of these three primary causes of viral hepatitis, namely HAV, HBV, and HCV. 

Worldwide, over 400 million people are infected with some form of chronic HBV. HBV is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The economic consequences of infection with HBV are staggering. Primary prevention through universal vaccination of neonates and adolescents is likely to have the largest impact on curtading this disease. ... 

The ISO-DALT technique has been used to investigate the pattern of proteins in sera from patients with, for example, Hodgkin s disease, Waldenstrbm s macroglobulinemia, and myeloma (L4, T3). In addition, it has proved a valuable tool in the study of the protein matrix of animal-and human-based quality control sera (C7). The technique has also been successfully applied to the analysis of particular proteins, e.g., the apoli-poproteins (Zl). Complementary studies, using nondenatured samples of sera from patients with, for example, myeloma, WaldenstrOm s macroglobulinemia, hepatic cirrhosis and of the lipoproteins have also been carried out (E3, E4, L3) and are reviewed by Latner (L2). 

---